|
Kevin Curran MD
Pediatric Hematologist-Oncologist
Memorial Sloan Kettering Cancer Center
USA
|
Kevin J. Curran, MD is an Associate Attending on the Transplant and Cellular Therapy Service at Memorial Sloan Kettering and Assistant Professor in Department of Pediatrics at New York Presbyterian Hospital and Weill Cornell Medical School. He is the Director of the Immune Effector Cell (IEC) Program at MSK and Interim Co-Director of the Cell Therapy and Cellular Engineering Facility (CTCEF). Dr. Curran’s research is on the clinical translation of novel cellular therapies for children with cancer. Specifically, the use of genetically and non-genetically modified T cells including chimeric antigen receptor (CAR) T cells and viral specific cytotoxic T lymphocytes (CTLs) for patients with refractory malignancies and/or viral infections. Dr. Curran has conducted multi-center trials in the use of CD19-specific CAR T cells for pediatric/young adults patients with relapse/refractory leukemia. He has demonstrated the impact of lymphodepleting chemotherapy on initial response and long-term durability of CAR T cells and is current research is focused on the pharmacokinetics of conditioning chemotherapy in both cellular therapy and allogeneic stem cell transplantation.